InflaRx N.V. (IFRX)
| Market Cap | 172.42M +74.3% |
| Revenue (ttm) | -38,532 -82.3% |
| Net Income | -33.30M |
| EPS | -0.33 |
| Shares Out | 147.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,952 |
| Open | 1.230 |
| Previous Close | 1.240 |
| Day's Range | 1.150 - 1.239 |
| 52-Week Range | 0.798 - 2.949 |
| Beta | 2.42 |
| Analysts | Strong Buy |
| Price Target | 8.41 (+619.06%) |
| Earnings Date | Nov 3, 2026 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u... [Read more]
Financial Performance
In 2025, InflaRx's revenue was 29,331, a decrease of -82.31% compared to the previous year's 165,789. Losses were -45.63 million, -0.93% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price target is $8.41, which is an increase of 619.06% from the latest price.
News
InflaRx Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Izicopan’s development is centered on renal disease, led by ANCA vasculitis, with additional IgAN, RPGN and aHUS studies planned. Current funding is expected to extend through 2029.
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx sees up to $2B peak sales for izicopan in vasculitis, plans 2027 trials
InflaRx (IFRX) announced that it intends to begin two Phase 2 trials of izicopan in ANCA-associated vasculitis in 2027, with first data readout anticipated in 2028. The program is expected…
InflaRx Transcript: CMD 2026
Izicopan’s AAV program centers on a renal-focused, placebo-controlled phase II and a parallel steroid-replacement study, alongside planned renal-disease programs. Market research estimated $1.65bn base-case AAV peak sales and ~$2bn with broader use.
InflaRx Press release: FY 2026
InflaRx issued a press release on November 3, 2026, disclosing material business information to investors.
InflaRx Slides: FY 2026
InflaRx has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 3, 2026.
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027,...
InflaRx Announces November Investor Events
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx to present pre-clinical izicopan data at Kidney Week 2026
InflaRx (IFRX) announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, Octob...
InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026
Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx appoints Alperovich as SVP, Global Head of Clinical Development
InflaRx (IFRX) announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President, SVP, & Global Head of Clinical Development, effective October 1, 2026. Alperovich joins InflaRx from...
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx to Host Virtual Capital Markets Day
Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.
InflaRx Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A strategic shift to renal diseases, especially ANCA vasculitis, is supported by strong clinical data and a favorable safety profile for the lead candidate, izicopan. The withdrawal of a key competitor in Europe has created a major market opportunity, and recent financing ensures funding through 2029.
InflaRx initiated with a Buy at Needham
Needham initiated coverage of InflaRx (IFRX) with a Buy rating and $8 price target InflaRx’s izicopan offers potentially significant upside in ANCA-associated vasculitis as a next-generation oral C5aR...
InflaRx Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is active, with phase II trials set to begin early next year and broader renal indications under consideration.
InflaRx Announces Participation in September Investor Conferences
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Earnings release: Q2 2026
InflaRx released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
InflaRx files $250M mixed securities shelf
09:22 EDT InflaRx (IFRX) files $250M mixed securities shelf
InflaRx Registration statement: Registration filing
InflaRx filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for AA...
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded InflaRx (IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Following Q1 earnings, sentiment is increasingly supported by a constructive view…